Oncological Complications of Excess GH in Acromegaly (original) (raw)
References
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102. Google Scholar
Giovanucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51(suppl. 3):34-41. Google Scholar
Melmed SM. Acromegaly and cancer: Not a problem? _J Clin Endocrinol Metab_2001;86:2929-2934. Google Scholar
Chan JM, Stampfer MJ, Giovanucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 1998;279:563-566. Google Scholar
Matzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-1118. Google Scholar
Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: A population based, casecontrol study. J Natl Cancer Inst 1998;90:911-915. Google Scholar
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-497. Google Scholar
Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17:421-424. Google Scholar
Ma J, Pollack MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J N Cancer Inst 1999;91:620-625. Oncological Complications of Excess GH in Acromegaly25
Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC. Colon cancer and polyps in acromegaly: Increased risk associated with family history of colon cancer. Clin Endocrinol 1990;32:65-71. Google Scholar
Ituarte EA, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med 1984;101:627-628. Google Scholar
Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39:1-16. Google Scholar
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12:71-79. Google Scholar
Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apopatosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188. Google Scholar
Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997;272:25602-25607. Google Scholar
Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-415. Google Scholar
Orme SM, McNally RJQ, Cartwright RA, Belchetz PE for the United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-2734. Google Scholar
Nabarro JD. Acromegaly. Clin Endocrinol 1987;26:481-512. Google Scholar
Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Endocrinol 1988;223:327-335. Google Scholar
Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990;59:55-62. Google Scholar
Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med 1991;151:1629-1632. Google Scholar
Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF. Acromegaly and gastrointestinal cancer. Cancer 1991;68:1673-1677. Google Scholar
Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol 1997;47:323-327. Google Scholar
Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol 1998;49:441-445. Google Scholar
Mestrón A, Webb SM for the SEEN (Sociedad Española de Endocrinolog ía y Nutrición). Spanish Acromegaly Register (Registro Español de Acromegalia-REA): Regional prevalence, morbidity and mortality. Endocrine Society, San Francisco, June 2002 (abstract). Google Scholar
Bates PR, Carson MN, Wass JAH. Surgical outcomes for acromegaly vary widely: A report on behalf of the UK national acromegaly study group. In: 83rd Annual Meeting of the Endocrine Society, 2001; abstract P2-179.
Carson MN, Bates PR, Wass JAH. Somatostatin analog therapy for acromegaly in clinical practice: A report on behalf of the UK national acromegaly study group. In: 83rd Annual Meeting of the Endocrine Society, 2001; abstract P2-190.
Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor 1 in transgenic mice. Endocrinology 1989;124:40-48. Google Scholar
Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, Palmiter RD. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988;123:2827-2833. Google Scholar
Ohneda J, Ulshen MH, Fuller CR, D'Ercole AJ, Lund PK. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 1997;112:444-454. Google Scholar
Jenkins PJ, Besser M. Acromegaly and cancer: A problem. J Clin Endocrinol Metab 2001;86:2935-2941. Google Scholar
Jenkins PJ, Frajese V, Jones A-M, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP, Besser GM. IGF-1 and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3218-3221. Google Scholar
Murphy LJ, Bell GI, Friesen HH. Growth hormone stimulates sequential induction of c-myc and insulin-like growth factor I expression in vivo. Endocrinology 1987;120:1806-1812. Google Scholar
Sumantran VN, Feldman EL. Insulin-like growth factor 1 regulates c-myc and GAP-43 messenger ribonucleic acid expresión in SH-SY5Y human neuroblastoma cells. Endocrinology 1993;132:2017-2023. Google Scholar
Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-151. Google Scholar
Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995;36:268-273. Google Scholar
Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JAH, Dowling RH. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996;38:775-783. Google Scholar
Jenkins PJ, Veysey MJ, Thomas LA. Increased serum deoxycholic acid levels in acromegalic patients with colorectal neoplasia. J Endocrinol 1997;152(suppl.):74. Google Scholar
Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, Di Sarno A, Lombardi G. Effect of two years of growth hormone and insulin-like growth factor-1 suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab 2000;85:3754-3761. Google Scholar